#25. INC. Innoviva, Buys $45M of Armata Pharmaceuticals, Inc. latest buy: 03/31/2022
During the last six months, Innoviva, bet big on ARMP:
Armata Pharmaceuticals is a biotechnology company focused on the development of bacteriophage therapeutics for the treatment of antibiotic-resistant infections using its bacteriophage-based technology. Co. is developing its phage product candidate for Pseudomonas aeruginosa, known as AP-PA02. Co. is also developing a phage product candidate for Staphylococcus aureus, known as AP-SA02, for the treatment of S. aureus bacteremia. In partnership with Merck and Co., Co. is developing both naturally-occurring and engineered phage candidates to target undisclosed infectious disease agents.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.